Reduced intensity allogeneic stem cell transplantation in multiple myeloma

Frontiers in Bioscience

Volumn 12, Issue 12, 2007, Pages 4384-4392

  Bensinger, William I ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Allogeneic stem cell transplantation; Immunotherapy; Multiple myeloma; Review

Indexed keywords

ALLOTRANSPLANTATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; HUMAN; MULTIPLE MYELOMA; RANDOMIZED CONTROLLED TRIAL; REVIEW; STEM CELL TRANSPLANTATION;

HUMANS; MULTIPLE MYELOMA; RANDOMIZED CONTROLLED TRIALS; STEM CELL TRANSPLANTATION; TRANSPLANTATION, HOMOLOGOUS;

EID: 34347261696     PISSN: 27686701     EISSN: 27686698     Source Type: Journal    
DOI: 10.2741/2395     Document Type: Article

References (53)

1. S. Kumar and K. C. Anderson: Drug insight: thalidomide as a treatment for multiple myeloma (Review). Nature Clinical Practice Oncology 2, 262-270 (2005) (Pubitemid 40812457)
2. K. C. Anderson, J. D. Shaughnessy, Jr., B. Barlogie, J.-L. Harousseau and G. D. Roodman: Multiple myeloma. In Hematology 2002: American Society of Hematology Education Program Book V. C. Broudy, J. L. Abkowitz and J. M. Vose, (eds) 214-240 American Society of Hemtology, Washington, DC (2002)
3. G. Tricot, D. H. Vesole, S. Jagannath, J. Hilton, N. Munshi and B. Barlogie: Graft-versus-myeloma effect: Proof of principle. Blood 87, 1196-1198 (1996) (Pubitemid 26043549)
4. L. F. Verdonck, H. M. Lokhorst, A. W. Dekker, H. K. Nieuwenhuis and E. J. Petersen: Graft-versus-myeloma effect in two cases. Lancet 347, 800-801 (1996) (Pubitemid 26091644)
5. J. Aschan, B. Lonnqvist, O. Ringden, G. Kumlien and G. Gahrton: Graft-versus-myeloma effect (Letter). Lancet 348, 346 (1996)
6. B. Barlogie, R. A. Kyle, K. C. Anderson, P. R. Greipp, H. M. Lazarus, D. D. Hurd, J. McCoy, S. R. Dakhil, K. S. Lanier, R. A. Chapman, J. N. Cromer, S. E. Salmon, B. Durie and J. C. Crowley: Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: final results of phase III US Intergroup Trial S9321. J Clin Oncol 24, 929-936 (2006) (Pubitemid 46638847)
7. R. Le Blanc, S. Montminy-Métivier, R. Bélanger, L. Busque, D. Fish, D.-C. Roy, J. Kassis, J. Boileau, R. Lavallée, D. Bélanger, F. Letendre, J. Hébert, G. Sauvageau, C. Perreault and J. Roy: Allogeneic transplantation for multiple myeloma: further evidence for a GVHD-associated graft-versus-myeloma effect. Bone Marrow Transplant 28, 841-848 (2001) (Pubitemid 33107611)
8. J. Libura, T. Hoffmann, J. Passweg, M. Gregor, G. Favre, A. Tichelli and A. Gratwohl: Graft-versus-myeloma after withdrawal of immunosuppression following allogeneic peripheral stem cell transplantation. Bone Marrow Transplant 24, 925-927 (1999) (Pubitemid 29500356)
9. H. Bertz, J. A. Burger, R. Kunzmann, R. Mertelsmann and J. Finke: Adoptive immunotherapy for relapsed multiple myeloma after allogeniec bone marrow transplantation (BMT): evidence for a graft-versusmyeloma effect. Leukemia 11, 281-283 (1997) (Pubitemid 27085174)
10. M. Salama, T. Nevill, D. Marcellus, P. Parker, M. Johnson, A. Kirk, D. Porter, S. Giralt, J. E. Levine, W. Drobyski, A. J. Barrett, M. Horowitz and R. H. Collins: Donor leukocyte infusions for multiple myeloma. Bone Marrow Transplant 26, 1179-1184 (2000)
11. R. H. Collins, Jr., O. Shpilberg, W. R. Drobyski, D. L. Porter, S. Giralt, R. Champlin, S. A. Goodman, S. N. Wolff, W. Hu, C. Verfaillie, A. List, W. Dalton, N. Ognoskie, A. Chetrit, J. H. Antin and J. Nemunaitis: Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation. J Clin Oncol 15, 433-444 (1997) (Pubitemid 27074209)
12. E. Alyea and J. Ritz: Induction of graft versus myeloma by donor lymphocyte infusions following allogeneic bone marrow transplant. In VI International Workshop on Multiple Myeloma 1997 K. C. Anderson (1997)
13. J. Mehta and S. Singhal: Graft-versus-myeloma (Review). Bone Marrow Transplant 22, 835-843 (1998)
14. N. Kroger, J. A. Perez-Simon, H. Myint, H. Klingermann, A. Shimoni, A. Nagler, R. Martino, A. Alegre, J. F. Tomas, R. Schwerdtfeger, M. Kiehl, A. Fauser, H. G. Sayer, A. Leon, J. Beyer, T. Zabelina, F. Ayuk, J. F. San Miguel, R. Brand and A. R. Zander: Relapse prior to autograft and chronic graft-versus-host disease are the strongest prognostic factors for outcome of melphalan/fludarabine-based dose-reduced allogeneic stem cell transplantation in patients with multiple myeloma. Biol Blood Marrow Transplant 10, 698-708 (2004) (Pubitemid 39272874)
15. H. Einsele, H. J. Schäfer, P. Bader, L. Plasswilm, P. Liebisch, M. Bamberg, C. Faul, H. Hebart and L. Kanz: Allografts after reduced intensity conditioning can induce long-term remission in patients with chemosensitive relapsed multiple myeloma (MM). Blood 100(Part 1), 635a, #2499 (2002)
16. K. Cwynarski, F. Dazzi, N. C. P. Cross, A. Yong, C. Craddock, J. Kaeda, E. Olavarria, E. Kanfer, J. F. Apperley and J. M. Goldman: Response to donor lymphocyte infusions (DLI) of patients with CML in relapse after allografting: a long-term follow-up study using RT-PCR. Blood 94(Suppl 1), 669a, #2968 (1999)
17. F. Dazzi, R. M. Szydlo, N. C. Cross, C. Craddock, J. Kaeda, E. Kanfer, K. Cwynarski, E. Olavarria, A. Yong, J. F. Apperley and J. M. Goldman: Durability of responses following donor lymphocyte infusions for patients who relapse after allogeneic stem cell transplantation for chronic myeloid leukemia. Blood 96, 2712-2716 (2000)
18. C. Helg, M. Starobinski, M. Jeannet and B. Chapuis: Donor lymphocyte infusion for the treatment of relapse after allogeneic hematopoietic stem cell transplantation (Review). Leuk Lymphoma 29, 301-313 (1998) (Pubitemid 28282327)
19. R. Storb, C. Yu, B. Sandmaier, P. McSweeney, G. Georges, R. Nash and A. Woolfrey: Mixed hematopoietic chimerism after hematopoietic stem cell allografts. Transplant Proc 31, 677-678 (1999) (Pubitemid 29127627)
20. P. A. McSweeney, D. Niederwieser, J. A. Shizuru, B. M. Sandmaier, A. J. Molina, D. G. Maloney, T. R. Chauncey, T. A. Gooley, U. Hegenbart, R. A. Nash, J. Radich, J. L. Wagner, S. Minor, F. R. Appelbaum, W. I. Bensinger, E. Bryant, M. E. D. Flowers, G. E. Georges, F. C. Grumet, H.-P. Kiem, B. Torok-Storb, C. Yu, K. G. Blume and R. F. Storb: Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects. Blood 97, 3390-3400 (2001)
21. D. G. Maloney, A. J. Molina, F. Sahebi, K. E. Stockerl-Goldstein, B. M. Sandmaier, W. Bensinger, B. Storer, U. Hegenbart, G. Somlo, T. Chauncey, B. Bruno, F. R. Appelbaum, K. G. Blume, S. J. Forman, P. McSweeney and R. Storb: Allografting with nonmyeloablative conditioning following cytoreductive autografts for the treatment of patients with multiple myeloma. Blood 102, 3447-3454 (2003) (Pubitemid 37314788)
22. C.-K. Lee, A. Badros, B. Barlogie, C. Morris, M. Zangari, A. Fassas, F. van Rhee, M. Cottler-Fox, J. Jacobson, R. Thertulien, F. Muwalla, S. Mazher, E. Anaissie and G. Tricot: Prognostic factors in allogeneic transplantation for patients with high-risk multiple myeloma after reduced intensity conditioning. Exp Hematol 31, 73-80 (2003) (Pubitemid 36110532)
23. S. Hoepfner, S. M. Probst, I. Breitkreutz, T. Moehler, A. Benner, H. Goldschmidt, A. D. Ho and M. Goerner: Non-myeloablative allogeneic transplantation as part of salvage therapy for relapse of multiple myeloma after autologous transplantation. Blood 100(Part 1), 859a, #3387 (2002)
24. S. Giralt, A. Aleman, A. Anagnostopoulos, D. Weber, I. Khouri, P. Anderlini, J. Molldrem, N. T. Ueno, M. Donato, M. Korbling, J. Gajewski, R. Alexanian and R. Champlin: Fludarabine/melphalan conditioning for allogeneic transplantation in patients with multiple myeloma. Bone Marrow Transplant 30, 367-373 (2002) (Pubitemid 35203509)
25. H. Einsele, H. J. Schafer, H. Hebart, P. Bader, C. Meisner, L. Plasswilm, P. Liebisch, M. Bamberg, C. Faul and L. Kanz: Follow-up of patients with progressive multiple myeloma undergoing allografts after reducedintensity conditioning. Br J Haematol 121, 411-418 (2003) (Pubitemid 36628332)
26. M. H. Qazilbash, R. Saliba, M. de Lima, C. Hosing, D. Couriel, A. Aleman, L. Roden, R. Champlin and S. A. Giralt: Second autologous or allogeneic transplantation after the failure of first autograft in patients with multiple myeloma. Cancer 106, 1084-1089 (2006)
27. F. Elice, R. Raimondi, A. Tosetto, A. D'Emilio, E. Di Bona, A. Piccin and F. Rodeghiero: Prolonged overall survival with second on-demand autologous transplant in multiple myeloma. Am J Hematol 81, 426-431 (2006) (Pubitemid 43787930)
28. N. Kroger, R. Schwerdtfeger, M. Kiehl, H. G. Sayer, H. Renges, T. Zabelina, B. Fehse, F. Togel, G. Wittkowsky, R. Kuse and A. R. Zander: Autologous stem cell transplantation followed by a dose-reduced allograft induces high complete remission rate in multiple myeloma. Blood 100, 755-760 (2002) (Pubitemid 34832597)
29. N. Kroger, H. G. Sayer, R. Schwerdtfeger, M. Kiehl, A. Nagler, H. Renges, T. Zabelina, B. Fehse, F. Ayuk, G. Wittkowsky, N. Schmitz and A. R. Zander: Unrelated stem cell transplantation in multiple myeloma after a reducedintensity conditioning with pretransplantation antithymocyte globulin is highly effective with low transplantation-related mortality. Blood 100, 3919-3924 (2002) (Pubitemid 35402053)
30. S. Galimberti, E. Benedetti, F. Morabito, F. Papineschi, V. Callea, R. Fazzi, C. Stelitano, F. Andreazzoli, F. Guerrini, E. Ciabatti, M. Martino, F. Nobile, P. Iacopino and M. Petrini: Prognostic role of minimal residual disease in multiple myeloma patients after non-myeloablative allogeneic transplantation. Leuk Res 29, 961-966 (2005) (Pubitemid 40840724)
31. K. S. Peggs, S. Mackinnon, C. D. Williams, S. D'Sa, D. Thuraisundaram, C. Kyriakou, E. C. Morris, G. Hale, H. Waldmann, D. C. Linch, A. H. Goldstone and K. Yong: Reduced-intensity transplantation with in vivo T-cell depletion and adjuvant dose-escalating donor lymphocyte infusions for chemotherapy-sensitive myeloma: Limited efficacy of graft-versus-tumor activity. Biol Blood Marrow Transplant 9, 257-265 (2003) (Pubitemid 40045612)
32. M. Mohty, J. M. Boiron, G. Damaj, A. S. Michallet, J. O. Bay, C. Faucher, V. Perreau, K. Bilger, D. Coso, A. M. Stoppa, R. Tabrizi, J. A. Gastaut, M. Michallet, D. Maraninchi and D. Blaise: Graft-versus-myeloma effect following antithymocyte globulin-based reduced intensity conditioning allogeneic stem cell transplantation. Bone Marrow Transplant 34, 77-84 (2004) (Pubitemid 39022961)
33. N. J. Bahlis, D. A. Stewart, M. L. Savoi, C. Brown, A. Daly, A. Chaundhry, J. Storek and J. A. Russell: Fludarabine-busulfan conditioning and in vivo T-cell depletion with reduced dose of ATG followed by allografting induces durable responses in patients with advanced multiple myeloma with no grade III-IV aGvHD. Blood 108(Part 1), 860a, #3029 (2006)
34. C. Crawley, M. Lalancette, R. Szydlo, M. Gilleece, K. Peggs, S. Mackinnon, G. Juliusson, L. Ahlberg, A. Nagler, A. Shimoni, A. Sureda, J.-M. Boiron, H. Einsele, R. Chopra, A. Carella, J. Cavenagh, A. Gratwohl, F. Garban, A. Zander, B. Björkstrand, D. Niederwieser, G. Gahrton and J. F. Apperley: Outcomes for reduced-intensity allogeneic transplantation for multiple myeloma: an analysis of prognostic factors from the Chronic Leukemia Working Party of the EBMT. Blood 105, 4532-4539 (2005) (Pubitemid 40720805)
35. C. Crawley, S. Iacobelli, B. Bjorkstrand, J. F. Apperley, D. Niederwieser and G. Gahrton for the Chronic Leukemia Working Party of the EBMT: Reduced intensity conditioning for myeloma: lower non-relapse mortality but higher relapse rates compared to myeloablative conditioning. Blood in press (2007)
36. A. M. Carella, E. Lerma, S. Nati, A. Congiu, E. Rossi, M. Spriano and R. Vimercati: Reduced intensity conditioning regimen for allografting following autografting has strong anti-myeloma activity and delays disease progression compared to tandem autografting. Blood 108(Part 1), 20a, #51 (2006)
37. F. Garban, M. Attal, M. Michallet, C. Hulin, J. H. Bourhis, I. Yakoub-Agha, T. Lamy, G. Marit, F. Maloisel, C. Berthou, M. Dib, D. Caillot, B. Deprijck, N. Ketterer, J. L. Harousseau, J. J. Sotto and P. Moreau: Prospective comparison of autologous stem cell transplantation followed by dose-reduced allograft (IFM99-03 trial) with tandem autologous stem cell transplantation (IFM99-04 trial) in high-risk de novo multiple myeloma. Blood 107, 3474-3480 (2006)
38. N. Kroger, G. Schilling, H. Einsele, P. Liebisch, A. Shimoni, A. Nagler, J. A. Perez-Simon, J. F. San Miguel, M. Kiehl, A. Fauser, R. Schwerdtfeger, H. Wandt, H. G. Sayer, H. Myint, H. Klingemann, T. Zabelina, J. Dierlamm, A. Hinke and A. R. Zander: Deletion of chromosome band 13q14 as detected by fluorescence in situ hybridization is a prognostic factor in patients with multiple myeloma who are receiving allogeneic dose-reduced stem cell transplantation. Blood 103, 4056-4061 (2004) (Pubitemid 38685344)
39. B. Bruno, M. Rotta, F. Patriarca, N. Mordini, B. Allione, F. Carnevale-Schianca, L. Giaccone, R. Sorasio, P. Omedè, I. Baldi, S. Bringhen, M. Massaia, M. Aglietta, A. Levis, A. Gallamini, R. Fanin, A. Palumbo, R. Storb, G. Ciccone and M. Boccadoro: A comparison of allografting with autografting for newly-diagnosed myeloma. N Engl J Med 356, 1110-1120 (2007) (Pubitemid 46425595)
40. 166HO-DOTMP plus melphalan followed by peripheral blood stem cell transplantation in patients with multiple myeloma: Results of two phase 1/2 trials. Blood 102, 2684-2691 (2003) (Pubitemid 37193613)
41. A. Dispenzieri, G. A. Wiseman, M. Q. Lacy, M. R. Litzow, P. M. Anderson, D. A. Gastineau, A. Tefferi, D. J. Inwards, I. N. Micallef, S. M. Ansell, L. Porrata, M. A. Elliott, J. A. Lust, P. R. Greipp, S. V. Rajkumar, R. Fonseca, T. E. Witzig, C. Erlichman, J. A. Sloan and M. A. Gertz: A phase I study of 153Sm-EDTMP with fixed highdose melphalan as a peripheral blood stem cell conditioning regimen in patients with multiple myeloma. Leukemia 19, 118-125 (2005) (Pubitemid 40090086)
42. G. A. Kennedy, S. Durrant, J. Butler, J. Morton, R. Western, M. L. Bartlett, R. Allison and D. J. Macfarlane: Outcome of myeloablative allogeneic stem cell transplantation in multiple myeloma with a 153Sm-EDTMP-based preparative regimen. Leukemia 19, 879-880 (2005) (Pubitemid 40663115)
43. W. I. Bensinger, P. J. Martin, B. Storer, R. Clift, S. J. Forman, R. Negrin, A. Kashyap, M. E. D. Flowers, K. Lilleby, T. R. Chauncey, R. Storb and F. R. Appelbaum: Transplantation of bone marrow as compared with peripheral-blood cells from HLA-identical relatives in patients with hematologic cancers. N Engl J Med 344, 175-181 (2001) (Pubitemid 32064138)
44. D. J. Macfarlane, S. Durrant, M. L. Bartlett, R. Allison and A. J. Morton: 153Sm EDTMP for bone marrow ablation prior to stem cell transplantation for haematological malignancies. Nucl Med Commun 23, 1099-1106 (2002) (Pubitemid 35398984)
45. S. Giralt, W. Bensinger, M. Goodman, R. Champlin, J. Eary, R. Wendt, J. Rajendran and R. Ghalie: Long-term follow-up of 83 patients with multiple myeloma (MM) treated on a phase I-II study of skeletal targeted radiotherapy (STR) using 166Ho-DOTMP plus melphalan with or without total body irradiation (TBI) and autologous hematopoietic stem cell transplant (AHSCT). Blood 100(Part 1), 179a, #670 (2002)
46. H. J. Deeg, B. Storer, J. T. Slattery, C. Anasetti, K. C. Doney, J. A. Hansen, H.-P. Kiem, P. J. Martin, E. Petersdorf, J. P. Radich, J. E. Sanders, H. M. Shulman, E. H. Warren, R. P. Witherspoon, E. M. Bryant, T. R. Chauncey, L. Getzendaner, R. Storb and F. R. Appelbaum: Conditioning with targeted busulfan and cyclophosphamide for hemopoietic stem cell transplantation from related and unrelated donors in patients with myelodysplastic syndrome. Blood 100, 1201-1207 (2002) (Pubitemid 34864272)
47. R. Champlin, S. Giralt, J. Gajewski, J. Hester, M. Körbling and A. Deisseroth: CD8 depleted donor lymphocytes for CML relapsing post BMT. ISEH 23, 939 (1995)
48. Z. Y. Lu, M. Condomines, K. Tarte, L. Nadal, M. C. Delteil, J. F. Rossi, C. Ferrand and B. Klein: B7-1 and 4-1BB ligand expression on a myeloma cell line makes it possible to expand autologous tumor-specific cytotoxic T cells in vitro. Exp Hematol 35, 443-453 (2007)
49. N. Kroger, B. Shaw, S. Iacobelli, T. Zabelina, K. Peggs, A. Shimoni, A. Nagler, T. Binder, T. Eiermann, A. Madrigal, R. Schwerdtfeger, M. Kiehl, H. G. Sayer, J. Beyer, M. Bornhauser, F. Ayuk, A. R. Zander and D. I. Marks: Comparison between antithymocyte globulin and alemtuzumab and the possible impact of KIR-ligand mismatch after dose-reduced conditioning and unrelated stem cell transplantation in patients with multiple myeloma. Br J Haematol 129, 631-643 (2005) (Pubitemid 40825825)
50. M. A. Hussein, J. R. Berenson, R. Niesvizky, N. C. Munshi, K. L. Harrop, M. McDonald and J. G. Drachman: A phase I humanized anti-CD40 monoclonal antibody (SGN-40) in patients with multiple myeloma. Blood 106(Part 1), 723a, # 2572 (2005)
51. S. Gerull, M. Goerner, A. Benner, U. Hegenbart, U. Klein, H. Schaefer, H. Goldschmidt and A. D. Ho: Longterm outcome of nonmyeloablative allogeneic transplantation in patients with high-risk multiple myeloma. Bone Marrow Transplant 36, 963-969 (2005) (Pubitemid 41741559)
52. S. Y. Ma, A. K. Lie, W. Y. Au, C. S. Chim, Y. L. Kwong and R. Liang: Non-myeloablative allogeneic peripheral stem cell transplantation for multiple myeloma. Hong Kong Medical Journal 10, 77-83 (2004) (Pubitemid 38477918)
53. R. Sorasio, L. Giaccone, F. Patriarca, V. Montefusco, S. Guidi, A. Busca, R. Scime, G. Console, G. Milone, G. Marotta, A. Dominietto, M. Rotta, M. Falda, A. Bacigalupo, A. Bosi, P. Corradini, R. Fanin, S. Pollichieni, B. Bruno and M. Boccadoro: Unrelated donor hematopoietic cell transplantation after nonmyeloablative conditioning for patients with high risk multiple myeloma. Blood 108(Part 1), 901a, #3158 (2006)